Eight Years Tumor Control with Pazopanib for a Metastatic Resistant Epithelioid Hemangioendothelioma

Overview

Journal Clin Sarcoma Res

Publisher Biomed Central

Date 2015 May 14

PMID 25969727

Citations 23

Authors

Olivia Bally

Louis Tassy

Bertrand Richioud

Anne-Valerie Decouvelaere

Jean-Yves Blay

Olfa Derbel

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Epithelioid hemangioendothelioma is a rare connective tissue tumor of vascular origin. It is most commonly found in young to middle aged women, and its clinical behavior is remakably variable from an indolent metastatic tumor to an aggressive rapidly growing neoplasm. Most tumors are diagnosed in an advanced unresectable phase and when clinically aggressive, require systemic cytotoxic treatment of sarcoma. Then, the 5-year survival rate after chemotherapy does not exceed 30%. Antiangiogenics are active in selected sarcoma subtypes: pazopanib, the only anti angiogenic registered agent for sarcoma provides a median PFS of 4.5 months only in the pivotal study. Their activity in EHE has been reported but long term outcome of these patients remain unreported. We report a case of a female patient with HEH who was treated with pazopanib for almost 8 years. Pazopanib therapy resulted in clinical improvement of symptoms and durable stabilization of liver tumors and lung lesions.

Conclusion: Pazopanib is a promising therapeutic option in patients with HEH.

Citing Articles

The challenges of hepatic epithelioid hemangioendothelioma: the diagnosis and current treatments of a problematic tumor.

Atyah M, Sun Y, Yang Z Orphanet J Rare Dis. 2024; 19(1):449.

PMID: 39616351 PMC: 11608485. DOI: 10.1186/s13023-024-03354-z.

Comprehensive evaluation of clinical outcomes in hepatic epithelioid hemangioendothelioma subsets: insights from SEER Database and departmental cohort analysis.

Wang B, Chen X, Li R, Ai B, Ye F, Zhao J Front Immunol. 2024; 15:1491922.

PMID: 39502705 PMC: 11534872. DOI: 10.3389/fimmu.2024.1491922.

Challenging diagnosis of primary hepatic epithelioid hemangioendothelioma in a patient with familial Mediterranean fever and hypothyroidism: A rare case report.

Alarashi L, Hamodi L, Abdallah L, Alali M, Saifo M Heliyon. 2024; 10(19):e38704.

PMID: 39403458 PMC: 11471504. DOI: 10.1016/j.heliyon.2024.e38704.

Dual immunotherapy alternating with anti-PD-1 antibody plus liposomal doxorubicin show good efficacy in prostate epithelioid hemangioendothelioma: a case report.

Zhang J, Ye Q, Yang X, Li T, Huang S, Zhou P Front Immunol. 2024; 15:1384111.

PMID: 38947327 PMC: 11211375. DOI: 10.3389/fimmu.2024.1384111.

Irreversible Electroporation as a Valid Treatment Option for Hepatic Epithelioid Hemangioendothelioma: An International Multicenter Experience.

Narayanan G, Spano A, Gentile N, Shnayder-Adams M, Gurusamy V, Levi D Cardiovasc Intervent Radiol. 2024; 47(7):883-890.

PMID: 38844684 PMC: 11239779. DOI: 10.1007/s00270-024-03770-5.

References

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Lauffer J, Zimmermann A, Krahenbuhl L, Triller J, Baer H . Epithelioid hemangioendothelioma of the liver. A rare hepatic tumor. Cancer. 1996; 78(11):2318-27. DOI: 10.1002/(sici)1097-0142(19961201)78:11<2318::aid-cncr8>3.0.co;2-i. View

Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied B, Hallscheidt P . Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006; 107(9):2108-21. DOI: 10.1002/cncr.22225. View

Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R . High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology. 2009; 251(2):447-56. DOI: 10.1148/radiol.2512081403. View

Thin L, Wong D, De Boer B, Ferguson J, Adams L, MacQuillan G . Hepatic epithelioid haemangioendothelioma: challenges in diagnosis and management. Intern Med J. 2009; 40(10):710-5. DOI: 10.1111/j.1445-5994.2009.02043.x. View

Park M, Ravi V, Araujo D . Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010; 22(4):351-5. DOI: 10.1097/CCO.0b013e32833aaad4. View

van der Graaf W, Blay J, Chawla S, Kim D, Bui-Nguyen B, Casali P . Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379(9829):1879-86. DOI: 10.1016/S0140-6736(12)60651-5. View

Makhlouf H, Ishak K, Goodman Z . Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer. 1999; 85(3):562-82. DOI: 10.1002/(sici)1097-0142(19990201)85:3<562::aid-cncr7>3.0.co;2-t. View

Lin J, Ji Y . CT and MRI diagnosis of hepatic epithelioid hemangioendothelioma. Hepatobiliary Pancreat Dis Int. 2010; 9(2):154-8. View

10.

Ishak K, Sesterhenn I, Goodman Z, Rabin L, Stromeyer F . Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases. Hum Pathol. 1984; 15(9):839-52. DOI: 10.1016/s0046-8177(84)80145-8. View

11.

Kelly H, ONeil B . Response of epithelioid haemangioendothelioma to liposomal doxorubicin. Lancet Oncol. 2005; 6(10):813-5. DOI: 10.1016/S1470-2045(05)70392-2. View

12.

Tolkach Y, Petrov S, Lerut E, van Poppel H . Epithelioid hemangioendothelioma of the kidney treated with sunitinib. Onkologie. 2012; 35(6):376-8. DOI: 10.1159/000338944. View

13.

Sleijfer S, Ray-Coquard I, Papai Z, Cesne A, Scurr M, Schoffski P . Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC.... J Clin Oncol. 2009; 27(19):3126-32. DOI: 10.1200/JCO.2008.21.3223. View

14.

Chevreau C, Cesne A, Ray-Coquard I, Italiano A, Cioffi A, Isambert N . Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013; 119(14):2639-44. DOI: 10.1002/cncr.28109. View

15.

Lee Y, Chung M, Jeong K, Hahn C, Hong K, Kim Y . Pleural epithelioid hemangioendothelioma. Yonsei Med J. 2008; 49(6):1036-40. PMC: 2628035. DOI: 10.3349/ymj.2008.49.6.1036. View

16.

Woelfel C, Liehr T, Weise A, Langrehr J, Kotb W, Pacyna-Gengelbach M . Molecular cytogenetic characterization of epithelioid hemangioendothelioma. Cancer Genet. 2012; 204(12):671-6. DOI: 10.1016/j.cancergen.2011.11.007. View

17.

Leahy M, Ray-Coquard I, Verweij J, Cesne A, Duffaud F, Hogendoorn P . Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2006; 43(2):308-15. DOI: 10.1016/j.ejca.2006.09.014. View

18.

Blay J, Van Glabbeke M, Verweij J, Van Oosterom A, Le Cesne A, Oosterhuis J . Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2002; 39(1):64-9. DOI: 10.1016/s0959-8049(02)00480-x. View

19.

Sangro B, Inarrairaegui M, Fernandez-Ros N . Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib. Rare Tumors. 2012; 4(2):e34. PMC: 3401162. DOI: 10.4081/rt.2012.e34. View

20.

Agulnik M, Yarber J, Okuno S, von Mehren M, Jovanovic B, Brockstein B . An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2012; 24(1):257-63. DOI: 10.1093/annonc/mds237. View